PerSeptive and BioSepra agree patent dispute:
This article was originally published in Clinica
Executive Summary
PerSeptive Biosystems' three-year legal battle with BioSepra and Sepracor has been settled out of court, with PerSeptive getting an unspecified sum and BioSepra gaining a non-exclusive licence to sell its HyperD product using PerSeptive's perfusion chromatography patents. PerSeptive is continuing its patent infringement action against Pharmacia Biotech, seeking punitive damages.